Olivier Gay1, Marion Plaze1, Catherine Oppenheim1, Raphael Gaillard1, Jean-Pierre Olié1, Marie-Odile Krebs1, Arnaud Cachia1. 1. From the INSERM UMR 894, Centre de Psychiatrie & Neurosciences, CNRS GDR 3557, Institut de Psychiatrie, Paris, France (Gay, Plaze, Oppenheim, Gaillard, Olié, Krebs, Cachia); the Université Paris Descartes, Sorbonne Paris Cité, Paris, France (Gay, Plaze, Oppenheim, Gaillard, Olié, Krebs, Cachia); the Service Hospitalo-Universitaire, Centre Hospitalier Sainte-Anne, Paris, France (Gay, Plaze, Gaillard, Olié, Krebs); the Service d'Imagerie Morphologique et Fonctionnelle, Centre Hospitalier Sainte-Anne, Paris, France (Oppenheim); the CNRS UMR 8240, Laboratoire de Psychologie du Développement et de l'Éducation de l'Enfant, Paris, France (Cachia); and the Institut Universitaire de France, Paris, France (Cachia).
Abstract
BACKGROUND: Several clinical and radiological markers of early neurodevelopmental deviations have been independently associated with cognitive impairment in patients with schizophrenia. The aim of our study was to test the cumulative and/or interactive effects of these early neurodevelopmental factors on cognitive control (CC) deficit, a core feature of schizophrenia. METHODS: We recruited patients with first-episode schizophrenia-spectrum disorders, who underwent structural MRI. We evaluated CC efficiency using the Trail Making Test (TMT). Several markers of early brain development were measured: neurological soft signs (NSS), handedness, sulcal pattern of the anterior cingulate cortex (ACC) and ventricle enlargement. RESULTS: We included 41 patients with schizophrenia in our analysis, which revealed a main effect of ACC morphology (p = 0.041) as well as interactions between NSS and ACC morphology (p = 0.005), between NSS and handedness (p = 0.044) and between ACC morphology and cerebrospinal fluid (CSF) volume (p = 0.005) on CC measured using the TMT-B score - the TMT-A score. LIMITATIONS: No 3- or 4-way interactions were detected between the 4 neurodevelopmental factors. The sample size was clearly adapted to detect main effects and 2-way interactions, but may have limited the statistical power to investigate higher-order interactions. The effects of treatment and illness duration were limited as the study design involved only patients with first-episode psychosis. CONCLUSION: To our knowledge, our study provides the first evidence of cumulative and interactive effects of different neurodevelopmental markers on CC efficiency in patients with schizophrenia. Such findings, in line with the neurodevelopmental model of schizophrenia, support the notion that CC impairments in patients with schizophrenia may be the final common pathway of several early neurodevelopmental mechanisms.
BACKGROUND: Several clinical and radiological markers of early neurodevelopmental deviations have been independently associated with cognitive impairment in patients with schizophrenia. The aim of our study was to test the cumulative and/or interactive effects of these early neurodevelopmental factors on cognitive control (CC) deficit, a core feature of schizophrenia. METHODS: We recruited patients with first-episode schizophrenia-spectrum disorders, who underwent structural MRI. We evaluated CC efficiency using the Trail Making Test (TMT). Several markers of early brain development were measured: neurological soft signs (NSS), handedness, sulcal pattern of the anterior cingulate cortex (ACC) and ventricle enlargement. RESULTS: We included 41 patients with schizophrenia in our analysis, which revealed a main effect of ACC morphology (p = 0.041) as well as interactions between NSS and ACC morphology (p = 0.005), between NSS and handedness (p = 0.044) and between ACC morphology and cerebrospinal fluid (CSF) volume (p = 0.005) on CC measured using the TMT-B score - the TMT-A score. LIMITATIONS: No 3- or 4-way interactions were detected between the 4 neurodevelopmental factors. The sample size was clearly adapted to detect main effects and 2-way interactions, but may have limited the statistical power to investigate higher-order interactions. The effects of treatment and illness duration were limited as the study design involved only patients with first-episode psychosis. CONCLUSION: To our knowledge, our study provides the first evidence of cumulative and interactive effects of different neurodevelopmental markers on CC efficiency in patients with schizophrenia. Such findings, in line with the neurodevelopmental model of schizophrenia, support the notion that CC impairments in patients with schizophrenia may be the final common pathway of several early neurodevelopmental mechanisms.
Authors: Stephen J Wood; Murat Yücel; Dennis Velakoulis; Lisa J Phillips; Alison R Yung; Warrick Brewer; Patrick D McGorry; Christos Pantelis Journal: Schizophr Res Date: 2005-06-15 Impact factor: 4.939
Authors: Armin Raznahan; Deanna Greenstein; Nancy Raitano Lee; Liv S Clasen; Jay N Giedd Journal: Proc Natl Acad Sci U S A Date: 2012-06-11 Impact factor: 11.205
Authors: Amy Deep-Soboslay; Thomas M Hyde; Joseph P Callicott; Marc S Lener; Beth A Verchinski; José A Apud; Daniel R Weinberger; Brita Elvevåg Journal: Brain Date: 2010-07-17 Impact factor: 13.501
Authors: Min-Seong Koo; James J Levitt; Dean F Salisbury; Motoaki Nakamura; Martha E Shenton; Robert W McCarley Journal: Arch Gen Psychiatry Date: 2008-07
Authors: Alan S Brown; Sophia Vinogradov; William S Kremen; John H Poole; Raymond F Deicken; Justin D Penner; Ian W McKeague; Anna Kochetkova; David Kern; Catherine A Schaefer Journal: Am J Psychiatry Date: 2009-04-15 Impact factor: 18.112
Authors: Neeltje E M van Haren; Fruhling Rijsdijk; Hugo G Schnack; Marco M Picchioni; Timothea Toulopoulou; Matthias Weisbrod; Heinrich Sauer; Theo G van Erp; Tyrone D Cannon; Matti O Huttunen; Dorret I Boomsma; Hilleke E Hulshoff Pol; Robin M Murray; Rene S Kahn Journal: Biol Psychiatry Date: 2012-02-16 Impact factor: 13.382
Authors: João V Nani; Caroline Dal Mas; Camila M Yonamine; Vanessa K Ota; Cristiano Noto; Sintia I Belangero; Jair J Mari; Rodrigo Bressan; Quirino Cordeiro; Ary Gadelha; Mirian A F Hayashi Journal: Int J Neuropsychopharmacol Date: 2020-07-22 Impact factor: 5.176